A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 in subjects with Clostridium difficile infection (CDI)
- Registry ID
- EUCTR2010-020941-29
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start date
- 2010-10-08
- Completion date
- 2012-11-12
- Last update
- 2026-08-16
Conditions
- Clostridium difficile infection
Summary
To evaluate the efficacy of a 10-day twice daily (b.i.d.) oral administration of 3 doses of ACT-179811 on cure.
Locations
- , , Italy
- , , UK
- , , Germany
- , , Sweden
View on source registry